OTRIVIN ® is a drug based on Xylometazoline hydrochloride
THERAPEUTIC GROUP: Nasal decongestants
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications OTRIVIN ® Xylometzoline
OTRIVIN ® is used as a nasal decongestant in diseases of the upper respiratory tract cooling.
Mechanism of action OTRIVIN ® Xylomethazoline
OTRIVIN ® is a Xylithazoline-based drug, sympathomimetic amine used as a nasal decongestant during upper respiratory tract infections characterized by mucosa congestion and thick mucus hypersecretion.
Introduced directly through the nostrils into the respiratory shaft, Xylomethazoline interacts with high affinity with the alpha 1 adrenergic receptors, exposed by the vascular smooth muscle, causing an intense process of vasoconstriction on the small vessels of the respiratory mucosa.
This mechanism is realized with the reduction of the mucosal edema and mucus secretion and with the subsequent restoration of the normal patency of the upper respiratory tract, thus considerably limiting the possible incidence of systemic side effects.
Studies carried out and clinical efficacy
XYLOMETAZOLINE IN THE PREVENTION OF? ™ EPISTASSIS.
Br J Anaesth. 2010 Oct; 105 (4): 501-5. doi: 10.1093 / bja / aeq205. Epub 2010 Aug 3.
Study demonstrating that treatment with Xylometazoline may reduce bleeding or severity of β-epistaxis in patients who undergo subsequent maxilo-facial surgical therapy, exercising the classic vasoconstrictor action.
CLINICAL EFFICACY OF? ™ OXIMETAZOLINA
Eur J Clin Pharmacol. 2011 Jan; 67 (1): 19-23. doi: 10.1007 / s00228-010-0941-z. Epub 2010 Nov 11.
Clinical trial that compares the various medicinal products on the market with a nasal decongestant effect, showing that Xylometazoline and? ™ Oximetazoline have the same clinical efficacy and the same rapidity of action.
ABUSE OF XYLOMETAZOLIN AND CARDIOVASCULAR COMPLICATIONS
Neurologist. 2011 Jan; 17 (1): 41-3. doi: 10.1097 / NRL.0b013e3181d2ab04.
Case report that reports the appearance of circulatory problems, complicated by a heart attack, following the maximum abuse of sympathomimetic nasal amines such as Xilometazoline.
Method of use and dosage
OTRIVIN ®
Nasal spray and nasal drops from 1 mg of Xilometazoline hydrochloride per ml of product.
In adults it is generally recommended to apply 2-3 drops per nostril or one spray per nostril 2-3 times a day as needed.
It is recommended not to extend the therapy beyond 5-7 days of treatment.
Warnings OTRIVIN ® Xylometzoline
The presence of a sympathomimetic amine, as active ingredient of OTRIVIN ®, imposes the utmost caution in the use of the drug in patients with cardiovascular diseases, and in particular in hypertensives, in patients treated with other vasoconstrictors and in hyper-responsive patients adrenergic drugs.
It is advisable in such cases that the doctor individually assesses the prescription appropriateness of the drug by deciding from time to time based on the patient's clinical conditions.
Prolonged use of sympathomimetics, including nasally, could result in addiction, thus reducing the therapeutic efficacy of the drug.
Maximum caution in the use of OTRIVIN ® is also recommended for pregnant women and elderly patients suffering from kidney disease.
PREGNANCY AND BREASTFEEDING
The use of OTRIVIN ® during pregnancy and in the subsequent period of breastfeeding is generally contraindicated, given the potential systemic vasoconstrictor power.
Interactions
The patient on antidepressant medication should avoid the use of OTRIVIN ® during the whole therapeutic process and up to two weeks after suspension.
Contraindications OTRIVIN ® Xylometzoline
The use of OTRIVIN ® is contraindicated in patients who are hypersensitive to the active substance or to one of its excipients, in patients with cardiovascular diseases, hyperthyroidism and glaucoma.
Contraindications to the use of OTRIVIN ® also extend to children under the age of 12 and to patients on antidepressant therapy, up to 2 weeks after stopping therapy.
Undesirable effects - Side effects
The use of OTRIVIN ® could determine the appearance of local adverse reactions such as dryness of the nasal mucosa and burning.
Fortunately, the systemic adverse reactions responsible for serious clinical conditions are rarer.
Note
OTRIVIN ® is a non-prescription drug.
